Fly News Breaks for July 21, 2015
NBIX
Jul 21, 2015 | 08:09 EDT
Leerink resumed shares of Neurocrine with an Outperform rating and $67 price target. The firm says its survey of 51 physicians who treat Tardive dyskinesia and specialist checks on endometriosis support its view that both NBI-98854 and Elagolix could achieve blockbuster status.
News For NBIX From the Last 2 Days